Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

7 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Development and Characterization of Treprostinil Palmitil Inhalation Aerosol for the Investigational Treatment of Pulmonary Arterial Hypertension.
Plaunt AJ, Islam S, Macaluso T, Gauani H, Baker T, Chun D, Viramontes V, Chang C, Corboz MR, Chapman RW, Li Z, Cipolla DC, Perkins WR, Malinin VS. Plaunt AJ, et al. Among authors: viramontes v. Int J Mol Sci. 2021 Jan 7;22(2):548. doi: 10.3390/ijms22020548. Int J Mol Sci. 2021. PMID: 33430435 Free PMC article.
Development and Preclinical Evaluation of New Inhaled Lipoglycopeptides for the Treatment of Persistent Pulmonary Methicillin-Resistant Staphylococcus aureus Infections.
Plaunt AJ, Rose SJ, Kang JY, Chen KJ, LaSala D, Heckler RP, Dorfman A, Smith BT, Chun D, Viramontes V, Macaluso A, Li Z, Zhou Y, Mark L, Basso J, Leifer FG, Corboz MR, Chapman RW, Cipolla D, Perkins WR, Malinin VS, Konicek DM. Plaunt AJ, et al. Among authors: viramontes v. Antimicrob Agents Chemother. 2021 Jun 17;65(7):e0031621. doi: 10.1128/AAC.00316-21. Epub 2021 Jun 17. Antimicrob Agents Chemother. 2021. PMID: 33941518 Free PMC article.
Correction for Plaunt et al., "Development and Preclinical Evaluation of New Inhaled Lipoglycopeptides for the Treatment of Persistent Pulmonary Methicillin-Resistant Staphylococcus aureus Infections".
Plaunt AJ, Rose SJ, Kang JY, Chen KJ, LaSala D, Heckler RP, Dorfman A, Smith BT, Chun D, Viramontes V, Macaluso A, Li Z, Zhou Y, Mark L, Basso J, Leifer FG, Corboz MR, Chapman RW, Cipolla D, Perkins WR, Malinin VS, Konicek DM. Plaunt AJ, et al. Among authors: viramontes v. Antimicrob Agents Chemother. 2022 Nov 15;66(11):e0125622. doi: 10.1128/aac.01256-22. Epub 2022 Oct 12. Antimicrob Agents Chemother. 2022. PMID: 36222535 Free PMC article. No abstract available.
The pharmacokinetic profile of brensocatib and its effect on pharmacodynamic biomarkers including NE, PR3, and CatG in various rodent species.
Basso J, Chen KJ, Zhou Y, Mark L, LaSala D, Dorfman A, Atalla M, Chun D, Viramontes V, Chang C, Leifer F, McDonald PP, Cipolla DC. Basso J, et al. Among authors: viramontes v. Front Pharmacol. 2023 Jul 19;14:1208780. doi: 10.3389/fphar.2023.1208780. eCollection 2023. Front Pharmacol. 2023. PMID: 37538173 Free PMC article.
Spanish-Speaking Mothers' Experiences of School-Based Speech Therapy.
Irizarry-Pérez CD, Bell LM, Rodriguez MN, Viramontes V. Irizarry-Pérez CD, et al. Among authors: viramontes v. Lang Speech Hear Serv Sch. 2024 Feb 23:1-19. doi: 10.1044/2024_LSHSS-23-00043. Online ahead of print. Lang Speech Hear Serv Sch. 2024. PMID: 38394224
Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial.
Rovin BH, Barratt J, Heerspink HJL, Alpers CE, Bieler S, Chae DW, Diva UA, Floege J, Gesualdo L, Inrig JK, Kohan DE, Komers R, Kooienga LA, Lafayette R, Maes B, Małecki R, Mercer A, Noronha IL, Oh SW, Peh CA, Praga M, Preciado P, Radhakrishnan J, Rheault MN, Rote WE, Tang SCW, Tesar V, Trachtman H, Trimarchi H, Tumlin JA, Wong MG, Perkovic V; DUPRO steering committee and PROTECT Investigators. Rovin BH, et al. Lancet. 2023 Dec 2;402(10417):2077-2090. doi: 10.1016/S0140-6736(23)02302-4. Epub 2023 Nov 3. Lancet. 2023. PMID: 37931634 Clinical Trial.
Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial.
Heerspink HJL, Radhakrishnan J, Alpers CE, Barratt J, Bieler S, Diva U, Inrig J, Komers R, Mercer A, Noronha IL, Rheault MN, Rote W, Rovin B, Trachtman H, Trimarchi H, Wong MG, Perkovic V; PROTECT Investigators. Heerspink HJL, et al. Lancet. 2023 May 13;401(10388):1584-1594. doi: 10.1016/S0140-6736(23)00569-X. Epub 2023 Apr 1. Lancet. 2023. PMID: 37015244 Clinical Trial.